November 11th, 2020 | 13:22 CET
NEL ASA, dynaCERT, Bayer: Reallocation offers excellent opportunities
Table of contents:
Climate change mainstream again
The Corona Pandemic has been the number one topic of conversation in recent months; however, climate change will likely find its way back into mainstream media once life normalizes again. "Fridays For Future" and Greta, will once again call for the world to be saved, and politicians who are currently acting as corona saviors, such as Bavarian Prime Minister Markus Söder, will once again put the ban of the internal combustion engine on the agenda.
Green technology and hydrogen
This is precisely where dynaCERT Inc., which was founded in 2001, comes in. The basic idea of the Canadians is to reduce the pollutant emissions of diesel-powered vehicles. For this purpose, retrofitting units for diesel engines have been developed which use hydrogen as a catalyst. This reduces both fuel consumption and CO2 emissions in peak times, by up to 20%.
Trucks (still) in the foreground
The target group of dynaCERT is, however, not yet the millions of passenger cars, but primarily fleet operators. The goal is to retrofit the millions of trucks still running on diesel. With the specially developed software "HydraLitica" (TM) it is possible to monitor the fuel savings. Building on this platform, the Company recently announced additional services such as fleet management, route planning, driver safety and load management. The Company's technology is currently being tested in more than 400 vehicles.
Analysts extremely bullish
The analyst firm GBC Research seems to be highly impressed. The experts set the dynaCERT share at a clear buy. The target price was set at no less than CAD 2.20 by the end of 2021. As of yesterday, the share price was at CAD 0.50, offering considerable upside potential. The Canadians have definitely taken the pulse of the times.
Insiders started buying
At the moment, positive and negative reports are coming from the pharmaceutical and agricultural giant, Bayer AG. After the share price reached a 5-year low of EUR 40.36 last week, the first insiders started to buy. Bayer CEO, Werner Baumann, ordered shares worth around EUR 2.45 million. Also, Chief Financial Officer Wolfgang Nickl and Heiko Schipper, responsible for the health products business, increased their portfolio with shares for EUR 154,000 and EUR 309,000 respectively.
Hope for approval
The application for approval of Bayer's renal drug, Finerenon, in the USA and the European Union is also positive. The applications were submitted simultaneously to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Finerenon is considered a new treatment option for slowing the progression of chronic kidney disease. According to industry experts, the drug has a potential of up to EUR 1.5 billion per year.
Sword of Damocles Monsanto
However, the glyphosate controversy continues to dominate all news. The US judge in charge is putting pressure on the Leverkusen-based Company. He wants to resume negotiations in some unresolved cases. Bayer wanted to take the litigation off the table last summer with a large-scale settlement of USD 9.6 billion. However, this settlement was rejected by the court. According to the Bayer leadership, the settlement package increased to around EUR 11.6 billion as of the beginning of November. The uncertainty remains. In the last two weeks, the price of the Bayer stock has recovered by almost 20% and, from a chartist's point of view, is on the verge of the downward trend that began in June and currently stands at just under EUR 49. In the event of a successful breakthrough, the gap to EUR 52.60 should be closed quickly.
NEL ASA keeps hoarding orders
Almost every week the Norwegian hydrogen specialist can shine with new orders. This time the subsidiary, Nel Hydrogen US, received orders for PEM electrolyzer cell stacks worth more than USD 5.4 million from none other than Raytheon Technologies. Nel Hydrogen US is the exclusive supplier of electrolyzer stacks to the United States Navy. The stacks produce vital oxygen for the crews on several classes of nuclear-powered submarines.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.